Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Alterity Therapeutics ( (AU:ATH) ) is now available.
Alterity Therapeutics recently announced the publication of a significant neuroimaging measure from its bioMUSE Natural History Study in the Annals of Clinical and Translational Neurology. This measure, known as the MSA Atrophy Index, serves as an imaging marker for diagnosing and tracking the progression of Multiple System Atrophy. The announcement was marked as market-sensitive, as it coincided with a slight increase in the company’s stock price, reflecting its potential impact on Alterity’s market positioning and stakeholder interests.
More about Alterity Therapeutics
Alterity Therapeutics is a biotechnology company focused on developing therapeutic solutions for neurodegenerative diseases. The company is primarily engaged in research and development of treatments for conditions such as Multiple System Atrophy (MSA), utilizing novel biomarkers and imaging techniques to advance their clinical studies.
YTD Price Performance: 40.0%
Average Trading Volume: 18,225,535
Technical Sentiment Signal: Sell
Current Market Cap: A$128.9M
See more insights into ATH stock on TipRanks’ Stock Analysis page.